These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17424995)

  • 21. [Experimental research on the action of a derivative from a p-chloropenoxyisobutyric acid series on lipid parameters].
    Filip M; Hriscu A; Păduraru I; Rusu M
    Rev Med Chir Soc Med Nat Iasi; 1986; 90(1):156-60. PubMed ID: 3764166
    [No Abstract]   [Full Text] [Related]  

  • 22. CORONARY EFFECT OF FIBRATES ON PROTEINS AND ENZYMES WHICH HYDROLYZE TRIACYLGLYCEROLS.
    Francik R; Kryczyk J; Francik S
    Acta Pol Pharm; 2016; 73(3):579-88. PubMed ID: 27476274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ciprofibrate and lipid profile.
    Chandler HA; Batchelor AJ
    Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract]   [Full Text] [Related]  

  • 24. Differences in the formation of PPARalpha-RXR/acoPPRE complexes between responsive and nonresponsive species upon fibrate administration.
    Rodríguez C; Noé V; Cabrero A; Ciudad CJ; Laguna JC
    Mol Pharmacol; 2000 Jul; 58(1):185-93. PubMed ID: 10860941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pleiotropic effects of fibrates.
    Chinetti-Gbaguidi G; Fruchart JC; Staels B
    Curr Atheroscler Rep; 2005 Sep; 7(5):396-401. PubMed ID: 16105484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative hypolipidaemic and peroxisomal effects of ciprofibrate, clofibric acid, and their respective difluorocyclopropyl and 4-fluoro-substituted analogues in rat.
    Graham MJ; Winham MA; Old SL; Gray TJ
    Xenobiotica; 1996 Jul; 26(7):695-707. PubMed ID: 8819300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
    Kockx M; Princen HM; Kooistra T
    Thromb Haemost; 1998 Dec; 80(6):942-8. PubMed ID: 9869165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression.
    Post SM; Duez H; Gervois PP; Staels B; Kuipers F; Princen HM
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1840-5. PubMed ID: 11701475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of Fibrates as Important Scaffolds in Medicinal Chemistry.
    Giampietro L; Ammazzalorso A; Amoroso R; De Filippis B
    ChemMedChem; 2019 Jun; 14(11):1051-1066. PubMed ID: 30957432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of local lipotoxicity: a new renoprotective mechanism of peroxisome proliferator-activated receptor-alpha activation in hypertension and obesity?
    Zhao X
    Hypertens Res; 2009 Oct; 32(10):821-3. PubMed ID: 19680259
    [No Abstract]   [Full Text] [Related]  

  • 31. Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy.
    Haim M; Benderly M; Boyko V; Goldenberg I; Tanne D; Battler A; Goldbourt U; Behar S;
    Coron Artery Dis; 2006 Aug; 17(5):455-61. PubMed ID: 16845254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.
    Carrieri A; Giudici M; Parente M; De Rosas M; Piemontese L; Fracchiolla G; Laghezza A; Tortorella P; Carbonara G; Lavecchia A; Gilardi F; Crestani M; Loiodice F
    Eur J Med Chem; 2013 May; 63():321-32. PubMed ID: 23502212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3.
    Maillet EL; Margolskee RF; Mosinger B
    J Med Chem; 2009 Nov; 52(21):6931-5. PubMed ID: 19817384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrates: where are we now?
    Seth Loomba R; Arora R
    Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):91-6. PubMed ID: 19144670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrates, dyslipoproteinaemia and cardiovascular disease.
    Watts GF; Dimmitt SB
    Curr Opin Lipidol; 1999 Dec; 10(6):561-74. PubMed ID: 10680050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
    Schonfeld G
    Atherosclerosis; 1994 Dec; 111(2):161-74. PubMed ID: 7718018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
    Chinetti-Gbaguidi G; Staels B
    Pharmacogenomics; 2007 Nov; 8(11):1567-80. PubMed ID: 18034622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
    Schwandt P; Weisweiler P; Drosner M; Janetschek P
    Atherosclerosis; 1982 Apr; 42(2-3):245-9. PubMed ID: 7073803
    [No Abstract]   [Full Text] [Related]  

  • 39. Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
    Lupp A; Karge E; Deufel T; Oelschlägers H; Fleck C
    Arzneimittelforschung; 2008; 58(5):225-41. PubMed ID: 18589557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2-{3-[2-(4-chlorophenyl)ethoxy]phenylthio}-2-methylpropanoic acid: a fibrate-like compound with hypolipidemic and antidiabetic activity.
    Dell'Uomo N; Tassoni E; Brunetti T; Pessotto P; Sciarroni AF; Milazzo FM; De Angelis F; Peschechera A; Tinti MO; Carminati P; Giannessi F
    ChemMedChem; 2006 Jan; 1(1):49-53. PubMed ID: 16892334
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.